Covid-19 Live Updates: Contradicting Scientists, Trump Says Tightening Vaccine Guidelines ‘Sounds Like a Political Move’

Trump renews his criticism of the F.D.A., suggesting it may be driven by politics.

President Trump said Wednesday that the White House “may or may not” approve new Food and Drug Administration guidelines requiring outside experts to weigh in before the agency approves a coronavirus vaccine, and said the plan “sounds like a political move,” undercutting government scientists who had said the opposite just hours earlier.

The president’s comments to reporters in the White House briefing room came after four of the administration’s top health officials who are helping to steer the government’s coronavirus response appeared in front of a Senate panel in an effort to bolster public trust in the F.D.A.

The officials told the panel that they had complete faith in the agency and that science and data — not politics — were guiding its decisions.

Their testimony came as the F.D.A. prepared to issue stricter guidelines for the emergency authorization of any new coronavirus vaccine. That would add a new layer to the vetting process.

But Mr. Trump has insisted a vaccine may be ready as early as next month — and he sounded more than a little skeptical about the new guidelines.

“That has to be approved by the White House,” he said, adding, “We may or may not approve it.”

The president then said, “I think that was a political move more than anything else.”

Asked about it a second time, Mr. Trump doubled down, repeating that the White House “may or may not” approve the new guidelines.

At Wednesday’s Senate hearing, the doctors — Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases, Dr. Stephen M. Hahn, the commissioner of the Food and Drug Administration, Dr. Robert R. Redfield, the director of the Centers for Disease Control and Prevention, and Admiral Brett P. Giroir, the coronavirus testing czar — defended the scientific integrity of the F.D.A. amid mounting evidence that President Trump and his administration have interfered with their agencies’ decision-making and growing public doubts about a coronavirus vaccine.

In a show of public support that would have been unnecessary in the pre-Trump era, all four doctors pledged to personally take any vaccine approved by the F.D.A. and said they would encourage their families to do the same.

The feverish race for a coronavirus vaccine got an infusion of energy on Wednesday as Johnson & Johnson announced that it has begun the final stage of its clinical trials, the fourth company to do so in the United States, which has passed a grim milestone of 200,000 deaths from the pandemic.

Johnson & Johnson is a couple of months behind the leaders, but its vaccine trial will be by far the largest, enrolling 60,000 participants. The company said it could know by the end of this year if its vaccine works.

And its vaccine has potentially big advantages over some competitors. It uses a technology that has a long safety record in vaccines against other diseases. Its vaccine could require just one shot instead of two. And unlike other vaccine candidates, it does not have to be kept frozen as it is delivered to hospitals and other places where it will be given to patients, simplifying the logistics of hundreds of millions of doses.

“Big news,” Mr. Trump tweeted about the trial on Wednesday morning. “@FDA must move quickly!”

The president has repeatedly claimed that a vaccine will be ready before Election Day, and has urged federal regulators to act quickly to approve one, raising fears that they will bow to the pressure and rush their vetting process. The federal government’s Operation Warp Speed program has invested more than $10 billion in private companies’ coronavirus vaccines to date, including about $1.5 billion to Johnson & Johnson.

Facing criticism over secrecy, several companies — including Johnson & Johnson on Wednesday — have taken the rare step of releasing the detailed blueprints of their trials, which are typically considered proprietary. And the F.D.A. is expected this week to release stricter guidelines outlining the criteria it will use to vet clinical trial data.

“We need multiple vaccines to work,” said Dr. Dan Barouch, a virologist at Beth Israel Deaconess Medical Center who led the development of the technology used in Johnson & Johnson’s trial. “There are seven billion people in the world, and no single vaccine supplier will be able to manufacture at that scale.”

Johnson & Johnson’s advanced trial, known as a Phase 3 trial, started on Monday. At a news conference, Dr. Paul Stoffels, the company’s chief scientific officer, said the company might be able to determine by the end of the year if the vaccine is safe and effective.

Johnson & Johnson has begun manufacturing the vaccine on an industrial scale to build up a supply that can be released immediately if the vaccine is authorized, Dr. Stoffels said in an interview on Wednesday. He expected to have tens of millions of doses ready by the end of the year. “Then we can ramp up to many more batches,” he said.

Johnson & Johnson’s vaccine uses an adenovirus to carry a gene from the coronavirus into human cells. The cell then produces coronavirus proteins, but not the coronavirus itself. These proteins can potentially prime the immune system to fight off a later infection by the virus.

Adenovirus vaccines must be kept refrigerated but does not need to be frozen, as the two front-runner vaccines, by Moderna and Pfizer, do. The freezing requirement could make the distribution of those vaccines difficult, especially to places without advanced medical facilities.

Moderna and Pfizer’s vaccines also require two jabs given a few weeks apart, a significant logistical hurdle.

Federal health officials on Wednesday reported a sharp drop in the number of children from low-income families who received dental care, vaccinations and preventive screenings this spring, after the pandemic began, compared with the same period last year.

A data analysis found there were 1.7 million fewer vaccinations given to Medicaid beneficiaries 2 or younger, a drop of 22 percent, and 3.2 million fewer screenings to detect autism or developmental delays, a drop of 44 percent. Dental care dropped by 69 percent, with 7.6 million fewer tooth cleanings and other services.

Most of the decline took place in April, with the rate starting to pick back up, much more in some states than others, in May. “The absence of these vital health care services may have lifelong consequences for these vulnerable children,” Seema Verma, the U.S. administrator of Medicare and Medicaid, said in a statement.

She called on states, pediatricians, families and schools to make sure children catch up on overdue medical appointments, in part to avoid an increase in cases of highly contagious diseases like measles and mumps.

More recent data suggest that the vaccination rate is increasing again, Ms. Verma said, but not fast enough to catch up with last year’s rate. She pointed out that while many children had received medical care via telehealth during the pandemic, vaccinations and tooth cleanings cannot be provided that way. There are about 40 million children on Medicaid, the public health insurance program for the poor, and the Children’s Health Insurance Program, or CHIP.

The analysis also found that about 32,000 Medicaid and CHIP beneficiaries younger than 19 — less than 0.1 percent of all the children in the programs — were treated for Covid-19 through June, while more than 250,000 received a coronavirus test in that time frame. Fewer than 1,000 were hospitalized with Covid through June, according to the federal data.

The Metropolitan Opera announced Wednesday that the still-untamed pandemic has forced it to cancel its entire 2020-21 season, prolonging one of the gravest crises in the Met’s 137-year history and keeping the nation’s largest performing arts organization dark until next September.

The decision is likely to send ripples of concern through New York and the rest of the country as arts institutions grapple with the question of when it will be safe again to perform indoors. Far from being a gilded outlier, the Met may prove to be a bellwether.

The outbreak has kept the 3,800-seat opera house closed since mid-March, sapping it of more than $150 million in revenue and leaving roughly 1,000 full-time employees, including its world-class orchestra and chorus, furloughed without pay since April.

New York City will furlough more than 9,000 employees this year as it grapples with substantial budget deficits wrought by the pandemic.

Mayor Bill de Blasio made the announcement on Wednesday, a week after he revealed he would furlough much of his City Hall staff, himself included. The action will save the city about $21 million, on top of the roughly $860,000 to be saved with the City Hall furlough. The furloughs will last five workdays, and employees will have to take them between October and March 2021.

These actions will not move the budgetary needle much. This year the city closed its $88 billion budget with an unspecified $1 billion in labor savings. The mayor’s office has since been negotiating with labor unions to find those savings, and the furloughs indicate the kinds of measures the city will have to consider if it wants to avoid 22,000 layoffs.

“No one wants to see layoffs, but unfortunately they’re still on the table,” Mr. de Blasio said Wednesday. “This at least gives us a little more relief while we continue those conversations and try and find a larger solution.”

In other New York City news:

  • The city’s Health Department warned that the virus was spreading at increasing levels in several neighborhoods in Brooklyn and Queens, especially among some of the city’s Hasidic communities, which were devastated by Covid-19 in the spring but had seen few cases in the summer. “This is something that requires urgent action,” the mayor said on Wednesday, adding that the city health department had closed two yeshivas in connection with the uptick and that police officers would step up enforcement of public health rules.

  • The New Year’s Eve celebration in Times Square will be largely virtual this year, organizers said on Wednesday. Details on the ceremony were not immediately disclosed. But organizers said that the typical gathering of hundreds of thousands of revelers to watch a ball drop and be showered in confetti would be replaced by virtual events and a small group of people in the square “who will reflect the themes, challenges and inspirations of 2020.”

The school board in Kenosha decided in July to start the year virtually. After parents demanded in-person instruction, the board reversed itself in August, deciding to offer students the choice of full-time classroom learning or full-time remote learning. The teachers’ union criticized that decision, saying it put teachers and students at risk.

Wisconsin is experiencing a spike in cases, with an increase of about 150 percent in the past week compared with the average two weeks earlier. Most of the other urban districts in the state, including Racine, Milwaukee, Green Bay and Madison, started the year with virtual classes. In Kenosha, the state’s third-largest district, at least five students or staff members have tested positive for the virus since school started Sept. 14, according to updates on the district website.

Kenosha, which has been racked by protests over police brutality in recent weeks, is not the first city to experience teacher protests over Covid-19 policies. In two towns in Massachusetts, teachers refused to show up for training at the start of the year, citing concerns about safety.

The Kenosha district said it hoped to return all of its 41 schools to in-person instruction by next week.

In other news around the United States:

  • Wall Street’s sell-off resumed on Wednesday as a drop in the shares of large technology companies dragged stocks to their fifth decline in the last six sessions. The S & P 500 fell more than 2 percent while the tech-heavy Nasdaq composite dropped 3 percent.

France raised its Covid-19 alert level in a number of areas across the country on Wednesday, and the authorities ramped up restrictions on public gatherings in several cities to prevent the health system from buckling under an influx of patients.

The new measures, which will take effect in the coming days, include the total closure of all bars and restaurants in the cities of Aix-en-Provence and Marseille and a ban on public gatherings of more than 10 people in Paris and a handful of other French cities.

Olivier Véran, the health minister, said at a news conference on Wednesday evening that the situation in France was “continuing to deteriorate.” The positivity rate for the virus has passed 6 percent, he said.

Mr. Véran said that the authorities were particularly worried because French hospitals were starting to feel the strain from new Covid-19 patients, who now represent nearly 20 percent of patients in intensive care across the country.

France is still far from the wave of hospitalizations it suffered earlier this year, but Mr. Véran said it was becoming increasingly hard to defer treatments or surgeries to make room for Covid-19 patients, as was widely done during the nation’s lockdown last spring.

Mr. Véran said that the new restrictions would be temporary and re-evaluated on a week-by-week basis and that the government would do all it could to avoid a second nationwide lockdown. He urged citizens to help avoid that.

“You can’t be extremely vigilant on the bus, in the metro, at the office, in shops,” he said, “and then completely let up your vigilance when you are in a bar, at home, or with family and friends.”

In other news around the world:

  • Prime Minister Sophie Wilmes of Belgium has taken a novel approach to reversing a rise in cases in her country: She loosened the rules. Ms. Wilmes said on Wednesday that masks would be required only in crowded places, not everywhere outdoors, as she had ordered in the summer. And while she still encouraged people to be in close contact with no more than five others at a time, broader socializing will be allowed if people keep their distance from one another. Many Belgians have clearly grown tired of strict social restrictions. By simplifying and clarifying them, Ms. Wilmes was attempting to reinvigorate public support — not to defeat the virus, but to live with it.

Every day, New York Times journalists are chronicling and debunking false and misleading information that is going viral online. Today, Adam Satariano, a tech reporter, looks at a new study that found that young people are more likely to believe misinformation about the coronavirus:

As public health officials raise alarms about surging coronavirus cases among young people, new research suggests that Americans under 25 are most likely to believe virus-related misinformation about the severity of the disease and how it originated.

In a survey of 21,196 people in all 50 states and the District of Columbia, researchers identified a clear generational divide. Respondents 18 to 25 had an 18 percent probability of believing a false claim, compared with 9 percent for those over 65, according to the study, conducted by researchers from Harvard University, Rutgers University, Northeastern University and Northwestern University.

The results diverge from past research that said older people were more likely to share false news articles on social media. Last year, a paper published in Science found that people over the age of 65 were seven times as likely as those ages 30 to 44, the youngest group included in that survey, to share articles from websites that spread false information during the 2016 presidential campaign.

In the virus study, people were questioned to gauge their acceptance of 11 false claims. Those included false claims that the virus originated in people who ate bats, that taking antibiotics protects against the disease and that only people 60 or older are at risk of being infected.

“Across the 11 false claims,” the report said, “we find a clear pattern: The older the age group, the lower the average level of belief in false claims.”

Reporting was contributed by Matt Apuzzo, Aurelien Breeden, Michael Cooper, Ben Dooley, Rick Gladstone, Joseph Goldstein, Abby Goodnough, Mike Ives, Corina Knoll, Sharon LaFraniere, Patricia Mazzei, Raphael Minder, Zachary Montague, Aimee Ortiz, Tariq Panja, Campbell Robertson, Dana Rubinstein, Adam Satariano, Anna Schaverien, Christopher F. Schuetze, Sheryl Gay Stolberg, Kate Taylor, Noah Weiland, Billy Witz, Elaine Yu, Mihir Zaveri and Carl Zimmer.

Source Article